LitAlert ~~ GeneLit.com

    • Phase I trial of the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib and AKT inhibitor capivasertib in patients with BRCA1/2 and non-BRCA1/2 mutant cancers.
    • Yap TA, Kristeleit R, Michalarea V, Pettitt SJ, Lim JSJ, Carreira S, Roda D, Miller R, Riisnaes R, Miranda S, Figueiredo I, Nava Rodrigues D, Ward S, Matthews R, Parmar M, Turner A, Tunariu N, Chopra N, Gevensleben H, Turner NC, Ruddle R, Raynaud FI, Decordova SA, Swales KE, Finneran L, Hall E, Rugman P, Lindemann JPO, Foxley A, Lord CJ, Banerji U, Plummer R, Basu B, Lopez JS, Drew Y, de Bono JS.
    • Cancer Discov. 2020 Jun 12:CD-20-0163. doi: 10.1158/2159-8290.CD-20-0163. Epub ahead of print.
    • Prostate Cancer Risk by BRCA2 Genomic Regions.
    • Nyberg T, Frost D, Barrowdale D, Evans DG, Bancroft E, Adlard J, Ahmed M, Barwell J, Brady AF, Brewer C, Cook J, Davidson R, Donaldson A, Eason J, Gregory H, Henderson A, Izatt L, Kennedy MJ, Miller C, Morrison PJ, Murray A, Ong KR, Porteous M, Pottinger C, Rogers MT, Side L, Snape K, Tripathi V, Walker L, Tischkowitz M, Eeles R, Easton DF, Antoniou AC.
    • Eur Urol. 2020 Jun 9:S0302-2838(20)30345-6. doi: 10.1016/j.eururo.2020.05.005. Epub ahead of print.
    • Young onset breast cancer in Southern China - a 5-year clinico-pathological study from a multi-centre database.
    • Co M, Kwong A.
    • Cancer Treat Res Commun. 2020 May 30;24:100182. doi: 10.1016/j.ctarc.2020.100182. Epub ahead of print.